Reference 2016-378

REF:            2016-378

Subject:        Neuroendocrine Tumours

    

 

Request:

  1. In your trust, please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with neuroendocrine tumours
  2. Of these how many have carcinoid syndrome (E34.0)?
  3. Of the patients with neuroendocrine tumours (NETs), how many received with the following treatments:
  • Somatuline Autogel (lanreotide)
  • Somatuline LA (lanreotide)
  • Sandostatin LAR (octreotide LAR)
  • Octreotide
  • Afinitor (everolimus)
  • Sutent (sunitinib)
  1. Please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with acromegaly (ICD10 code E220 or ICD10 code D352), with the following treatments:
  • Somatuline Autogel (lanreotide)
  • Somatuline LA (lanreotide)
  • Sandostatin LAR (octreotide LAR)
  • Octreotide
  • Somavert (pegvisomant)
  • Signifor (pasireotide pamoate)

*To assist in sourcing the answer to my question specifically in respect of NETs, the below information may be of use.

In relation to patients with neuroendocrine tumours, these tumours are typically identified from pathology analysis, but may be coded using various ICD10 codes. The following may be commonly used:

  • C787 – Secondary malignant neoplasm of liver
  • C786 – Secondary malignant neoplasm of retroperitoneum and peritoneum
  • C772 – Secondary and unspecified malignant neoplasm of Intra-abdominal lymph nodes
  • C780 – Secondary malignant neoplasm of the lung
  • Z850 –  Personal history of malignant neoplasm of digestive organs

 

 

Response:

Please find information attached.

2016-378 FOI Request Neuroendocrine Tumours [90 kb] PDF

 

Visitor restrictions

To protect you and our staff during the current outbreak of Covid-19 we’ve put in place significant restrictions on hospital visitors.

Full details of these can be found on our website.

We would like to thank you for your understanding and helping us stop the spread of Covid-19.

Read More

Stay Home. Protect the NHS. Save Lives.

Close